# name
Targeted-pig trial on safety and immunogenicity of
                serum-derived extracellular vesicles enriched fractions obtained
                from Porcine Respiratory and Reproductive virus infections

# metadata.dc.description.abstract[].value
The Porcine Reproductive and Respiratory Syndrome Virus
                (PRRSV) is the etiological agent of one of the most important
                swine diseases with a significant economic burden worldwide.
                Unfortunately, available vaccines are partially effective
                highlighting the need of novel approaches. Previously, antigenic
                viral proteins were described in serum-derived extracellular
                vesicles (EVs) from pigs previously infected with PRRSV. Here, a
                targeted-pig trial was designed to determine the safety and
                immunogenicity of such extracellular vesicles enriched
                fractions. Our results showed that immunizations with
                EV-enriched fractions from convalescence animals in combination
                with montanide is safe and free of virus as immunizations with
                up-to two milligrams of EV-enriched fractions did not induce
                clinical symptoms, adverse effects and detectable viral
                replication. In addition, this vaccine formulation was able to
                elicit specific humoral IgG immune response in vaccinated
                animals, albeit variably. Noticeably, sera from vaccinated
                animals was diagnosed negative when tested for PRRSV using a
                commercial ELISA test; thus, indicating that this new approach
                differentiates vaccinated from infected animals. Lastly, after
                priming animals with EV-enriched fractions from sera of
                convalescence animals and boosting them with synthetic viral
                peptides identified by mass spectrometry, a distinctive high and
                specific IFN-\xCE\xB3 response was elicited. Altogether, our
                data strongly suggest the use of serum EV-enriched fractions as
                a novel vaccine strategy against PRRSV.

# metadata.dc.source[].value
Articles publicats en revistes (ISGlobal)

# metadata.dc.title[].value
Targeted-pig trial on safety and immunogenicity of
                serum-derived extracellular vesicles enriched fractions obtained
                from Porcine Respiratory and Reproductive virus infections